CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-22 | Aranda Richard Chief Medical Officer | Sale | −1,814 | $1.29 | $2K | 197,574 |
| 2023-06-08 | GALA RENEE D Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2023-06-08 | Cox Russell J. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2023-06-08 | Milligan Sandra Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2023-06-08 | Daniel Thomas O Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2023-06-08 | Burow Kristina Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −48,500 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −13,750 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −34,175 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −28,250 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −31,750 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −190,000 | 0 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +32,334 | 32,334 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +9,167 | 9,167 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +22,784 | 22,784 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +18,834 | 18,834 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +21,167 | 21,167 | ||
| 2023-05-05 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +126,667 | 126,667 | ||
| 2023-05-05 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −45,000 | 0 | ||
| 2023-05-05 | Aranda Richard Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −13,750 | 0 |
Page 11 of 14 · 262 trades